
Board MeetingNov 20, 2026, 04:01 PM
Kymera Therapeutics to Announce Atopic Dermatitis Trial Results Nov. 23
AI Summary
Kymera Therapeutics, Inc. announced that it will report results from its BROADEN2 Phase 2b clinical trial for KT-621, an oral STAT6 degrader, in patients with moderate to severe atopic dermatitis on Monday, November 23, 2026. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET. KT-621 is being developed as a potential treatment for various Type 2 inflammatory diseases.
Key Highlights
- Kymera Therapeutics to announce results from BROADEN2 Phase 2b clinical trial for KT-621 in atopic dermatitis on November 23, 2026.
- Press release with results to be issued at 7:00 a.m. ET.
- Video conference call and webcast to follow at 8:00 a.m. ET.
- KT-621 is an investigational oral degrader of STAT6 for Type 2 inflammation.
- KT-621 is also in clinical development for asthma.
- Potential to treat atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, and bullous pemphigoid.
Price Impact
More from KYMR